The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New ...

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

Michael Batnick said the outperformance of consumer discretionary stocks relative to consumer staples is "the most bullish ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

A new study documents the dramatic change in America's material diet from 1900 to 2020—ongoing shifts in US commodity ...

As I reported in yesterday’s Mail, another bespoke medical service is couriering Ozempic and other weight ... app for celebrities – were ‘off the charts’. She ended up having a drink ...

Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...

Trump's pick to lead the Health Department is targeting a multibillion-dollar ad market that's one of the biggest spenders on the airwaves.

The beef between the two hip-hop stars seemed to reach a point of no return after Lamar released his diss track "Not Like Us.